drugset / Trial / NCT01514487

Comparison of Three Liraglutide Formulations in Healthy Volunteers

NCT01514487

Phase 1 Completed 24 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Oceania. The aim of this trial is to test for bioequivalence between each of the two new liraglutide formulations at pH 7.9 and 8.15 and the planned Phase 3 formulation at pH 7.7.

Timeline

Start
2005-01-13
Primary completion
2005-03-30
Completion
2005-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 0.75 mg Other

Indications